目的：探讨胰岛素受体、p53肿瘤分子学指标在合并2型糖尿病乳腺癌患者肿瘤组织中的表达情况，并对其与2型糖尿病的关系及临床价值做出评判。方法合并2型糖尿病乳腺癌患者68例，对照非糖尿病乳腺癌组患者145例，取石蜡切片作胰岛素受体，p53指标的免疫组化检测。并分析比较两组指标的阳性率。结果在合并2型糖尿病组中，胰岛素受体阳性比例76.5%（52/68），阴性23.5%（16/68），对照组胰岛素受体阳性比例31.7%（46/145），阴性68.3%（99/145），二者在统计学上有差别（χ2=37.3，P<0.01）。在合并2型糖尿病组中，p53阳性比例66.2%（45/68），阴性33.8%（23/68），对照组p53阳性比例47.6%（69/145），阴性52.4%（76/145），二者在统计学上有差别（χ2=6.43， P<0.05）。结论在2型糖尿病合并乳腺癌患者肿瘤组织中胰岛素受体高表达，p53突变，预示患者不良预后，因加强随访及治疗。%Objective To investigate the expression of IR(insulin receptor)and p53 in the tumor of breast cancer patients with type 2 diabetes mellitus. Methods 68 breast cancer patients with type 2 diabetes mellitus who underwent surgery were analyzed retropectively. The expression of IR and p53 measured by immunohistochemistry(IHC)were compared to the 145 patients without type 2 diabetes mellitus. Results There was a statistically signiifcant difference of IR and p53 expression between the patients with type 2 diabetes mellitus and the non-ones. Conclusion There were more patients with IR and p53 positive in type 2 diabetes mellitus group, which might indicate the pathogenisis of breast cancer. However, if they exerted aprognostic effect on breast cancer patients need further study.
展开▼
